Ask AI
ProCE Banner Activity

CE / CME

Management of a Patient With Progressive Biliary Tract Cancer After Standard of Care Gemcitabine/Cisplatin Plus an Immune Checkpoint Inhibitor

Case Challenge

This Interactive Case Challenge features optimal management approaches for a patient with progressing advanced biliary tract cancer and addresses challenges faced by healthcare professionals in the management of patients who experience a treatment-related adverse event while receiving therapy.

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: December 30, 2025

Expiration: June 29, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients, Inc.

ProCE Banner

Supporters

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is designed to address the educational needs of oncologists, advanced practice providers, pharmacists, nurses, physician associates, and other HCPs involved in caring for patients with GEA or BTC. Additionally, it aims to empower patients with vital information to actively participate in their treatment decisions, fostering a collaborative approach to their care.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners in an effort to optimize treatment for patients with HER2+ GEA or BTC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate recent practice-changing data from clinical trials of HER2-targeted agents into treatment plans for HER2+ GEA and BTC to improve patient outcomes

  • Develop individualized treatment strategies for HER2+ GEA and BTC based on current and emerging evidence supporting the use of HER2-targeted therapies in this setting

  • Communicate emerging data and ongoing clinical trial opportunities in HER2+ GEA and BTC to educate colleagues and counsel patients, fostering a collaborative environment for decision-making in their treatment journey

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Shubham Pant, MD: consultant/advisor: Alligator Bioscience, Arcus, AskGene Pharma, AstraZeneca, Boehringer Ingelheim, BPGBio, Bristol Myers Squibb, Daiichi Sankyo, Immuneering, Ipsen, Janssen, Jazz, Merck, Nihon Medi-Physics, Novartis, Pfizer, Revolution Medicine, Theriva Biosciences, USWorldmeds; researcher (paid to institution): Amal Therapeutics, Arcus, Astellas, Boehringer Ingelheim, Bristol Myers Squibb, CG Pharmaceuticals, Elicio, Immuneering, ImmunoMET, Incyte, Janssen, Jazz, Novartis, Pfizer, Revolution Medicine; individual publicly traded stock/stock options: OncoMed, Telperian.

The planners and content peer reviewers from Decera Clinical Education and Smart Patients do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below:

Kristi K. Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Bristol Myers Squibb, DSI, Exelixis, Lilly, Pfizer, Sobi, Stemline.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 30, 2025, through June 29, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC dba Decera Clinical Education and Smart Patients. Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-9999-25-508-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days

Physician Associate Continuing Medical Education

AAPA CME Accreditation - AAPA

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until June 29, 2026. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Clinical Care Options, LLC dba Decera Clinical Education Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC dba Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.